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Overexpression of Aurora-A kinase has been correlated with cancer susceptibility and poor prognosis in several human cancers. In
this study, we evaluated the effect of inhibition of Aurora-A kinase on cell cycle progression and tumour cell survival after exposure to
ionising radiation (IR). Combined IR and Aurora-A inhibition by short interfering RNA (siRNA) or by PHA680632 (a selective Aurora
kinase inhibitor with submicromolar activity against Aurora-A) prior to IR led to an enhancement of radiation-induced annexin V
positive cells, micronuclei formation, and Brca1 foci formation only in cells with deficient p53. However, the drug brought about
additive to sub-additive interaction with radiation with regard to in vitro clonogenic survival. Cell cycle analysis revealed a high 44N
DNA content 24h after PHA680632 exposure. DNA content 44N was reduced dramatically when cells were irradiated combined
with PHA680632 simultaneously. In vivo xenografts (p53 /  HCT116) of a mice study showed enhanced tumour growth delay
(TGD) after the PHA680632 IR combinatorial treatment compared with IR alone. These results demonstrate that PHA680632 in
association with radiation leads to an additive effect in cancer cells, especially in the p53-deficient cells, but does not act as a
radiosensitiser in vitro or in vivo.
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The Aurora kinases constitute one family of serine/threonine
kinases whose activity is essential for the mitotic progression
(Nigg, 2001; Carmena and Earnshaw, 2003). Its peak expression is
from phase G2 to cytokinesis. There are three types of mammalian
Aurora kinases: Aurora-A, Aurora-B, and Aurora-C. Despite their
similarities, the three mammalian Aurora kinases show differences
in subcellular localisations, timing of activation and functions
during mitosis.
Aurora-B is one of the chromosomal passenger proteins that are
essential for a number of processes during mitosis. In mammalian
cells, Aurora-B forms a large chromosome passenger complex with
INCENP, surviving, and Borealin (Adams et al, 2001; Carmena and
Earnshaw, 2003; Gassmann et al, 2004). Aurora B function is
required for mitotic chromosome alignment, spindle checkpoint
function, and cytokinesis. Aurora-C has been shown to localise to
spindle poles in late stages of mitosis, and a recent report indicates
that it is a chromosome passenger.
Aurora-A is localised to the duplicated centrosomes and to the
spindle poles in mitosis. Several studies show a role of Aurora-A in
several processes required for building a bipolar spindle apparatus,
including centrosome maturation and separation. Aurora-A binds
to, and its kinase activity is regulated by, a protein called TPX2,
which is required for spindle assembly. Aurora-A recruits
important components for spindle assembly. Repression of
Aurora-A expression by RNA interference (RNAi) delays mitotic
entry in human cells, and overexpression of the kinase can
compromise spindle-checkpoint function as well as inhibit
cytokinesis (Hirota et al, 2003). Aurora-A possesses some
phosphorylation substrates such as BRCA1 (Ouchi et al, 2004)
and CDC25B in G2/M transition (Dutertre et al, 2004; Cazales et al,
2005). Aurora-A is implicated in p53 degradation via MDM2
(Katayama et al, 2004), which could further contribute to genomic
instability and transformation by abrogating the ability of the cell
to respond to DNA damage or other insults. Cells with over-
expression of Aurora-A can resist to taxol, and this overexpression
can inhibit radio-induced G2–M arrest (Anand et al, 2003). A
diminution of cisplatin-induced apoptosis has been observed in
MCF-7 cells and this effect is p53-dependent (Katayama et al,
2004).
Amplification of Aurora genes, as well as mRNA and protein
overexpression, has frequently been reported in many human
cancer cell lines: colon–rectum, breast, pancreas, and ovary.
Moreover, their genetic localisations (Aurora-A, 20q13; Aurora-B,
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s17q13) map to chromosomal loci frequently altered in tumours.
Aurora-A has been shown to act as an oncogene because
overexpression of wild-type Aurora-A or of a constitutive active
mutant transforms Rat1 and NIH 3T3 cells leading to colony
formation in soft agar assays. In addition, NIH 3T3 cells expressing
constitutively active Aurora-A can grow as solid tumours when
injected into nude mice. Overexpression of Aurora-A is likely to
induce a low level of genetic instability, through abnormal
centrosome duplication and the generation of aneuploidy. These
properties make the Aurora kinases attractive targets for anti-
cancer therapy; indeed, the first inhibitors have been tested in the
clinical setting. Several Aurora kinases inhibitors (Keen and
Taylor, 2004) have been described previously: ZM447439
(Ditchfield et al, 2003), Hesperadin (Hauf et al, 2003) and VX-
680 (Harrington et al, 2004) and, more recently, AZD1152
and MLN8054 and so on. The effect of combining Aurora-A
inhibition with IR is unknown, and the aim of this study was to
evaluate the influence of inhibition of Aurora-A kinase of tumour
radio-sensitivity by either a genetic inhibition using short
interfering RNA (siRNA) targeting Aurora-A or a pharmaco-
logical approach using a selective inhibitor PHA680632 (Soncini
et al, 2006).
MATERIALS AND METHODS
Cell lines
HCT116 human colorectal cancer cell lines (wild-type (wt),
p53 / ) (Bunz et al, 1998) were a kind gift by B Vogelstein
(Johns Hopkins, Baltimore) HT29 colorectal cancer cell line (p53
mutated) and A549 human non-small cell lung cancer (wild-type
p53) were obtained from the American Type Culture Collection
(Manassas, VA, USA). HCT116 and HT29 cells were maintained in
McCoy’s 5a medium (Gibco, Gergy Pouloisa, France) supplemen-
ted with 10% fetal bovine serum (ATGC), 1% PS (Gibco), 1%
L-glutamine (Eurobio, Courtaboul, France), 1mM sodium pyruvate
(Gibco), and 10mM HEPES (Sigma, Saint Louis, MO, USA) in
humidified atmosphere containing 5% CO2 at 371C. A549 was
maintained in RPMI-1640 medium (Eurobio) supplemented with
10% fetal bovine serum (ATGC), 1% PS (Gibco), 1% L-glutamine
(Eurobio), 1mM sodium pyruvate (Gibco), and 10mM HEPES
(Sigma).
Clonogenic survival assays
Clonogenic survival assays were studied in p53 wt and p53 / 
HCT116, HT29 (p53 and ras mutant) colorectal cancer cell lines
and A549 lung cancer cell line. Cells were seeded in triplicate into
six-well plates or a 25-cm
2 flask in a range of 100–80000 cells per
well, depending on the radiation dose that the cells received, the
test condition, and different cell lines, so as to yield 20–200
colonies per flask or well). Once the cells were attached, a single
dose of photon irradiation with and without the drugs was applied.
Cells were cultured in a 371C, 5% CO2 incubator for 10–14 days.
Individual colonies (450 cells per colony) were fixed and stained
for 20min with a solution containing crystal violet and methanol.
The plating efficiency (PE) represents the percentage of cells
seeded that grow into colonies under a specific culture condition of
a given cell line. The survival fraction, expressed as a function of
irradiation, was calculated as follows: Survival fraction (SF) at 2Gy
(SF2)¼colonies counted of 2Gy/(cells seeded of 2Gy*PE/100). In
the clonogenic survival curve, we normalised the different
conditions according to the control. The radiation dose enhance-
ment ratio (DER) by PHA680632 was calculated using the
following formula: DER¼(SF at an indicated dose of radiation
alone)/(SF at an indicated dose of radiationþPHA680632). Radio-
sensitisation is defined as the term used when PHA680632
increases the sensitivity of cells to radiation (as assessed by
clonogenic inhibition or apoptosis). This is calculated as per the
formula listed above and represented in the form of DER. Thus,
DER is defined as the ratio of surviving cells with radiation alone
compared with a combination of radiation and PHA680632
exposures. Dose enhancement ratio¼1 suggests an additive
radiation effect and DER41, a supra-additive effect as against a
sub-additive effect in the case of DERo1. A 200kV X-ray device
(0.66Gymin
 1) and 137-caesium source (1.85Gymin
 1) were used
in vitro.
Immunocytochemistry, foci, micronuclei, and antibodies
HCT116 cells were seeded in 12-well plates incubated with a
different concentration of PHA680632 for 1 or 24h and fixed in 4%
paraformaldehyde (Sigma) for 30min. Cells were then permeabi-
lised with PBS containing 0.1% Triton X-100 for 3min and
incubated with a 5mgml
 1 BSA/PBS blocking solution. Cells were
incubated with Phospho-T288 Aurora-A by a rabbit polyclonal
antibody (1:1000, Abcam, Cambridge, UK) and with b-tubulin by
a mouse monoclonal anti-b-tubulin (1:200, Cytoskeleton, Denver,
CO, USA) primary antibody, followed by incubation with a goat
anti-rabbit IgG conjugated to Alexa 555 fluorochrome (Molecular
Probes, Carlsbad, CA, USA) and an anti-mouse IgG Alexa 488
conjugate (1:500, Molecular Probes) secondary antibody. Chromo-
somes were stained with 1mgml
 1 Hoechst 33324 (Molecular
Probes) in PBS for 5min. Tri-colour images were merged using
Adobe Photoshop (v 8.0). Detection of micronuclei: cells were
transfected by siRNA Aurora-A or control for 24h, IR of 6 or 0Gy.
At 24h of incubation after IR, the cells were stained with Hoechst
33342 (Zhang et al, 2006). Micronuclei and multinuclei were
checked by fluorescence microscopy and morphologically classi-
fied according to standard criteria (Zhang et al, 2006). More than
400 cells were scored for each data point. BRCA1 foci test: cells
were transfected by siRNA Aurora-A or control for 24h, IR of 6 or
0Gy, 4h after incubation, and cells were fixed and stained with
1:500 antibody anti-BRCA1 (Santa Cruz) and 1:500 second
antibody goat anti-rabbit IgG Alexa 555. For the quantification of
BRCA1 foci, we counted only the number of the clearest foci with
high intensity in each cell and excluded those foci with low
intensity. A mouse monoclonal antibody against Aurora-A kinase
(BD Biosciences, Franklin Lakes, NJ, USA) at a 1:250 dilution was
used for western blotting.
Cell cycle analysis
Sham control and 6Gy-irradiated cells with and without drug
exposure were harvested by trypsinisation at the indicated time
after irradiation, washed with ice-cold PBS, fixed in 70% ethanol,
and stored at  201C. Prior to DNA analysis, DNA content was
labelled with 0.1mgml
 1 propidium iodide (PI) and 1mgml
 1
RNAse. Cell cycle analysis was performed by flow cytometry
analysis (FACS Calibur, BD Biosciences).
Annexin V staining analysis in FACS
Cells were collected by centrifugation and resuspended in 500ml
annexin labelling solution consisting of 5ml Annexin V FITC (BD
Biosciences) and incubated in the dark for 15min. A total of
0.1mgml
 1 PI was then added to the cell suspension, followed by
cytofluorimetric analysis on a FACS Vantage SE (BD Biosciences)
(Zhang et al, 2006).
Short interference RNA
The following siRNAs were followed for analyses: human Aurora-A
(Qiagen, Valencia, CA, USA), 50-AUUCUUCCCAGCGCGUUCC-30
(corresponding to nucleotides 155–173 relative to the start codon)
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sor 50-AUGCCCUGUCUUACUGUCA-30 (nucleotides 725–743) and
the data with the first have been shown (Hirota et al, 2003). A
double-stranded RNA non-specific (Dharmacon RNA Technolo-
gies, Cafayette, CO, USA) was used as a control. For Aurora-A
siRNA analysis, the oligonucleotide targeted to positions 725–743
was used unless indicated otherwise. Two siRNAs, p53 50-GA
CUCCAGUGGUAAUCCACTT-30 and 50-GUGAGCGCUUCGAGAU
GUUTT-30 (Qiagen), have been used for the silencing of p53, and
the second has been successfully confirmed in previous siRNA
experiments. The siRNA transfections were conducted with
Oligofectamine transfection reagent (Invitrogen, Carlsbad, CA,
USA). Annealing of the component siRNA strands and transfection
were performed as described previously (Elbashir et al, 2001).
Chemical Aurora-A inhibitors
Inhibitor of Aurora-A kinase, PHA-680632 (Soncini et al, 2006) (a
kind gift from Nerviano Medical Sciences, Milan, Italy), is a
specific inhibitor of Aurora kinases A, B, and C (relative molecular
mass: 501Da). The stock solution (10mM in DMSO) was aliquoted
and stored at  201C frozen until ready for use. It was shown to be
a potent inhibitor of all three Aurora kinases with IC50 values of 27,
135, and 120nM for Aurora-A, -B, and -C, respectively. For in vivo
use, PHA680632 was dissolved in 20% Tween-80 in 5% glucose
solution and was stable for 3 days at 41C. It is important to note
that different concentrations of various reagents were used in
different cell lines because of their relative sensitivity or resistance
to the reagents tested.
In vivo xenograft in nude mice
Female athymic nude mice 6–8 weeks of age (Janvier CERT 53940,
Le Genest St Isle, France) were used for the tumour xenograft
model. The in vivo experiments were carried out at the Institut
Gustave Roussy under the Animal Care license C94-076-11
(Ministere de l’Agriculture). A total of 3 10
6 p53 /  HCT116
cells were subcutaneously inoculated in the right flank of
each mouse. Treatment began when the tumour was at least
5mm in diameter. Mice were randomly allocated into four
groups (six mice per group): A, control; B, IR alone, 8Gy in
1 day; C, PHA680632 alone, 40mgkg
 1, b.i.d., for 4 days; D,
same dose of PHA680632 combined with IR (24h after the
first administration of PHA680632, similar schedule as IR alone)
for 4 days. Drug or vehicle control (same volume of 20% Tween-80
in 5% glucose solution) was administered intraperitoneally (i.p.).
The tumour size was measured twice a week using an electronic
caliper. Follow-up of individual mice was conducted. The tumour
volume was estimated from 2D tumour measurements using the
following formula: Tumour volume¼length (mm) width
2
(mm
2)/2.
Statistical analyses
For the polyploidy of cell cycle of different conditions, a two-tailed
t-test was used to calculate the P-value. The effect of PHA680632
and of dose of irradiation on the percentage of cells leading to
colony formation was tested by logistic regression. To avoid
repeated analyses and the increase of the a error rate, we studied
the interaction between PHA680632 and dose of irradiation. A
two-sided w
2 test was used to calculate the P-value of micronuclei
formation difference. The effects of treatments on tumour volume
were assessed using mixed models analysing the tumour volume at
D4, 8, 11, 15, and 18. This model allows us to analyse the effect of
treatment and the interaction between treatment and time, and to
analyse repeated measurements. Statistical analysis was performed
using SAS version 8.02 software (SAS Institute Inc., Cary, NC,
USA).
RESULTS
Selective Aurora kinase inhibitor, PHA680632, inhibited
colony formation in different cancer cell lines and induced
polyploidy
We first used a selective Aurora kinase inhibitor with potential
inhibition of Aurora-A, PHA680632, which has been described
recently (Soncini et al, 2006). Polyploidy has been shown to
correlate with Aurora kinases inhibition (Harrington et al, 2004),
and we used it as a surrogate of PHA680632 efficacy on Aurora
kinases. Cell cycle analysis showed that PHA680632 exposure at
concentrations ranging from 200 to 400nM induced polyploidy in
HCT116 cell line with a dose dependency effect for the induction of
polyploidy (data not shown). In Figure 1A, we show the percentage
of different cell cycle sub-populations: sub-G1, G1, S, G2–M, and
44N cells after exposure to different conditions: control, IR,
PHA680632 or PHA680632þIR combination. DMSO (as a control)
or 400nM PHA680632 was combined with a 6Gy irradiation. In the
two cell lines, we observe a significant increase of 44N cells sub-
population after 24h exposure of 400nM PHA680632 (P¼0.0081
and P¼0.0005 for p53wt and p53 /  HCT116, respectively). This
effect was more pronounced in p53 /  HCT116 cells than in
p53wt HCT116 cells. Exposure of cells to PHA680632 for 24h
induced 44N DNA content in the p53 /  HCT116 cell line (69%)
than in the p53 wild-type HCT116 cell line (47%), P¼0.0482.
When 6Gy irradiation was performed after 1h PHA680632
exposure, the 44N DNA content cell accumulation (44N cells
percentage) reduced dramatically in the p53wt HCT116 cell line
(reduced to 9.6%) when compared to the same cells exposed to
PHA680632 without irradiation P¼0.0068. A similar effect has
also been observed in the p53 /  HCT116 cell line (44N DNA
content cells reduced to 20% when 6Gy irradiation was performed
after 1h PHA680632 exposure), P¼0.0119.
In our study, we observed a remarkable inhibition of
phosphorylation of Aurora-A in T288 in the early mitotic cells
24h after PHA680632 treatment. Among the cells at the G2/M
transition (two centrosomes), we distinguished the G2 from the M
cells according to morphological criteria (condensation status of
chromosomes). We also observed the G2 cells component, which is
not in mitosis; these cells also present with marked phosphorylated
Aurora-A in T288, while in cells treated by PHA680632, the
phosphorylation of Aurora-A in T288 in these G2 cells has also
been completely inhibited (data not shown). Moreover, the entire
disorder of mitotic spindle in the cells treated by PHA680632
indicated a disturbed centrosome function following Aurora-A
kinase inhibition (Figure 1C).
In further clonogenic assay, PHA680632 (24h exposure) proved to
be an effective inhibitor of colony formation in vitro,w i t had o s e -
dependent effect at the range of 50nMto2.5mM in different cell lines.
Clonogenic survival of HCT116, HT29, and A549 cells exposed to a
concentration range of PHA680632 are shown in Figure 2.
PHA680632 could inhibit the colony formation even with a
concentration of 50–100nM in HCT116 cell lines, while 1mM of
PHA680632 induced only a slight clonogenic survival reduction in
HT29 cells. This colony formation inhibition by PHA680632 depends
on different characteristics of various cell lines and is probably
dependent on the p53 or ras status of the cells. We observed that the
p53 /  HCT116 is more resistant to this Aurora-A inhibitor alone
than the p53 wild-type counterparts. The resistant HT29 is p53 and
K-ras mutated, while the A549 with wild-type p53 is more sensitive.
Aurora-A inhibition by PHA680632 enhanced radiation
response in cancer cells, especially in p53-deficient cells
Since Aurora-A kinase has been shown to be implicated in p53
degradation, we subsequently explored the radiation response after
treatment by PHA680632 (24h exposure) in cancer cell lines with
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sdifferent p53 functional status. The p53 wild type and p53
knockout HCT116 cells A549 and HT29, another p53 mutant
cancer cell line, were chosen. Clonogenic survival assays (colony
formation) demonstrated an enhanced radiation response
(Figure 3A, ‘PHA norm ctrl’ is survival fraction of a different
irradiation dose combined with PHA680632 normalised with
‘control 0Gy’ that is, cell survival, no irradiation) when the cells
were irradiated 24h after exposure to PHA680632 in p53 / 
HCT116 cell line as well as in the p53wt HCT116 cell line.
As shown in Figure 3A, for p53wt HCT116 cell lines, statistic
analysis demonstrated that PHA680632 increased the radiation
effect (Po0.0001), but the effect of PHA680632 tended to reduce as
the radiation dose increased. This suggests a slightly sub-additive
effect (DER¼0.872 at 2Gy) in HCT116 p53wt cells treated with
PHA680632 before irradiation (again, the survival was normalised
to the survival curve control, no irradiation). Of interest, as shown
in Figure 3A, for p53 /  HCT116 cell lines, statistic analysis
demonstrated that PHA680632 increased the radiation effect
(Po0.0001), that there is an interaction between PHA680632 and
IR (P¼0.0806), and that the effect of PHA680632 increased along
with the radiation dose. This suggests rather a supra-additive effect
(DER¼1.348 at 1Gy and DER¼1.285 at 2Gy) of irradiation 24h
after exposure to 100nM PHA680632 in the p53 /  HCT116 cell
line. This might reflect a p53 dependency of the effect of
PHA680632 on radiation cell killing (Figure 3A). We then conducted
an apoptosis assay as defined by Annexin V staining in p53 /  and
p53wt HCT116 cells (cells were exposed to 100nM PHA680832
for 24h and then exposed to 6Gy irradiation). As shown in
Figure 3B, in p53 /  HCT116 cells, the percentage of apoptotic
cells (PI Annexinþ and PIþAnnexinþ) was 36.86±4.19
(PHA680632þIR) and 21.54±7.04 (IR alone) (Po0.0001), respec-
tively. There was an interaction between PHA680632 and IR, and
PHA680632 enhanced radiation-induced apoptosis in p53 / 
HCT116 cells. In their p53 wild-type counterparts, p53wt HCT116
cells, the percentage of apoptotic cells, was 37.64±13.96
(PHA680632þIR) and 33.38±12.36 (IR alone), respectively.
In the p53 mutant HT29 cell line, irradiation combined with
PHA680632 (1mM PHA680632 24h exposure before radiation) led
to a pronounced inhibition of colony formation as compared with
PHA680632 or irradiation alone. This statistical analysis demon-
strated that PHA680632 increased the radiation effect (Po0.0001)
(Figure 4A) (DER¼1.205 at 2Gy).
In the p53wt A549 cell line, a genetic inhibition of p53 by siRNA
(Figure 4B) was performed to assess the effect of p53 in response
to the combination of PHA680632 and irradiation. We found
an increase in radiation response (DER¼1.212 at 2Gy and
DER¼2.519 at 6Gy) to the combination of both 200nM
PHA680632 and IR in A549 cells transfected with an siRNA p53
compared to A549 cells transfected with control siRNA and treated
with both PHA680632 and IR under the same conditions. There is
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Figure 1 Influence of PHA680632 on cell cycle in p53wt vs p53 /  HCT116 cells. (A and B) analysis of the cell cycle. (A) Quantitative data of cell cycle
distribution after PHA680632 and 6Gy of irradiation in p53wt HCT116 (above) and p53 /  HCT116 (below) have been shown in the two histograms.
The mean values (percentage of sub-population of different cell cycle: sub-G1, G1, S, G2–M, and 44N cells is shown in different conditions: control, IR,
PHA680632, or PHA680632þIR combination) of three independent experiments are shown and bar errors represent s.e.m. Twenty-four hours exposure
to 400nM PHA680632 led to the apparition of 44N DNA content cells in the two HCT116 cell lines (P¼0.0081 and P¼0.0005 for p53wt and p53 / 
HCT116, respectively), PHA680632 induced a greater accumulation of cells with 44N DNA content in p53 /  HCT116 cell line when compared to their
p53 wild counterparts (P¼0.0482); a moderate G2–M block was observed 24h after 6Gy irradiation in the control cells. At 24h after 6Gy irradiation and
PHA680632, exposure dramatically reduced the percentage of cells with 44N DNA content cells compared with PHA680632 alone (P¼0.0068 and
P¼0.0119 for p53wt and p53 /  HCT116, respectively). (B) A representative cell cycle analysis in p53 /  HCT116 cells. (C) Immunofluorescence
images showing phospho-T288-Aurora-A (Pho-Aurora-A) in mitotic p53wt HCT116 cells after 24h exposure of 1mM PHA680632 (below) or control
(above). b-Tubulin and Hoechst were used to visualise microtubule and DNA, respectively.
Aurora-A inhibition p53-dependent radiosensitivity
Y Tao et al
1667
British Journal of Cancer (2007) 97(12), 1664–1672 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
san interaction between PHA680632 and IR (Po0.0001).
PHA680632 had little effect (DER¼0.994 at 2Gy) on radiation
response in the same cells transfected with control siRNA
(P¼0.6444) (Figure 4C). Thus, this selective Aurora kinases
inhibitor, PHA680632, seems to exert a more important influence
on the radiation response of cells with a non-functional p53.
P53 dependency of the influence of inhibition of Aurora-A
kinase by siRNA on radiation response in HCT116 cells
To confirm the effect of inhibition of Aurora-A kinase on tumour
cells’ response to radiation, we used a siRNA approach to inhibit
the expression of Aurora-A. The time response of Aurora-A
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Figure 2 Influence of PHA680632 on clonogenic survival in different cancer cell lines. Clonogenic survival assay of cell lines exposed to a concentration
range of PHA680632. (A) p53 /  HCT116; (B) p53wt HCT116; (C) HT29 (p53 mutated); (D) A549 (p53 wt).
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Figure 3 Influence of PHA680632 on the cellular response to irradiation in p53wt vs p53 /  HCT116 cells. (A) p53-dependent effect of the
PHA680632 on clonogenic survival after irradiation; the cells were exposed to 100nM PHA680632 for 24h and then irradiated. Data represent the mean of
three independent experiments in triplicate, and error bars represent s.d. for p53wt (left) and p53 /  (right) HCT116 cells. The surviving fraction after drug
exposureþirradiation is normalised to survival for the same cells treated with the drug alone in the absence of irradiation (plating efficiency: 68.7 and 87%,
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survival were: Po0.0001 for DMSO vs PHA norm ctrl, Po0.0001 for DMSO vs PHA in p53wt HCT116, and P¼0.0806 for DMSO vs PHA in p53 / 
HCT116. (B) Cytofluorimetric detection of apoptotic parameters in p53 wt (left) and p53 /  (right) HCT116 cells, respectively, exposed to 100nM for
24h PHA680832 and then irradiated (6Gy); 72h after irradiation, cells were stained with Annexin V and PI and analysed by FACS. Quantification of the data
were obtained; error bars represent s.d. For p53 /  HCT116, P-value was o0.0001 when comparing PHA680632 alone vs IRþPHA680632 and for IR
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selected led to a strong inhibition of Aurora-A expression in the
HCT116 cell line 24h after siRNA transfection (Figure 5A). We
then subsequently performed irradiation experiments 24h after
siRNA transfection. In the two HCT116 cell lines, p53 /  and
p53wt, a different response to IR after inhibition of Aurora-A
was observed (Figure 5A). We observed an increase in radiation
cell killing after siRNA Aurora-A transfection when compared
to siRNA control in the HCT116 p53 /  cell line (DER¼1.213
at 2Gy and DER¼1.454 at 4Gy) but not in the p53wt HCT116
cell line (DER¼0.803 at 2Gy) (Figure 5A). Indeed, this combina-
tion even seemed to exert an antagonistic effect on the p53wt
HCT116 cell line. This underscores the role of the p53 functional
status in the response after Aurora-A kinase inhibition and
irradiation.
We showed previously (Zhang et al, 2006) that IR indeed
induces the development of micronucleated cells and leads to
mitotic catastrophe. This type of cell death occurs during or
shortly after a dysregulated or failed mitosis and can be
accompanied by morphological alterations, such as micronuclei
and multinucleation (Okada and Mak, 2004). Micronuclei can be
considered a sign of mitotic catastrophe. We hypothesised that the
inhibition of Aurora-A kinase combined with irradiation could
induce mitotic catastrophe. Quantification of micronuclei after
transfection with siRNA control or Aurora-A showed no
significant difference in the number of cells with micronuclei
either in the absence (P¼0.8746) or after IR in the HCT116 wt cell
line (P¼0.5102) (Figure 5B). In the HCT116 p53 /  cell line,
siRNA Aurora-A transfection did not significantly affect the
number of micronuclei in the absence of irradiation (P¼0.614),
but we observed a significant increase in micronuclei formation
after 6Gy IR compared with siRNA control transfection: 42 vs
32% (P¼0.0018), respectively (Figure 5B). Thus, in the siRNA
Aurora-A transfected p53 /  HCT116 cells, there are more cells
with micronuclei induced by IR compared with siRNA control
transfection; however, this effect was not shown in p53wt HCT116.
It has been reported previously that BRCA1 is phosphorylated
at serine-308 by Aurora-A in the centrosome and has been
found to correlate with Aurora-A kinase in the G2–M
phase transition (Ouchi et al, 2004). Regarding the role of BRCA1
in DNA repair, cell cycle checkpoint, and especially the cellular
response to IR, we evaluated the influence of Aurora-A inhibition
using siRNA on BRCA1 foci formation. The p53 /  or p53wt
HCT116 cancer cells were transfected by siRNA Aurora-A
or siRNA control for 24h, then irradiated to 6 or 0Gy (sham
control). At 4h after IR, the cells were fixed and stained for BRCA1
foci detection. We observed more foci after IR in the nucleus
of p53 /  HCT116 cells when Aurora-A expression was inhibited
compared to transfection with siRNA control in p53 /  HCT116
cells (4.9 vs 3.6); however, in wt HCT116 cells, we could not
find any obvious difference between cells transfected by siRNA
Aurora-A and control (Figure 5C). This suggests that there
is a slight increase in radiation-induced BRCA1 foci after
Aurora-A inhibition in p53 /  HCT116 compared to p53wt
HCT116 cells.
In vivo experiments in subcutaneous xenograft models
using the PHA680632 and IR combination
To explore the radiation response by Aurora-A inhibition in vivo,
the inhibitor PHA680632 was used in subcutaneous p53 / 
HCT116 cell xenograft models. A marked tumour growth delay
(TGD) was found in animals treated with PHA680632 alone
(40mgkg
 1 i.p. b.i.d. for 4 days) compared with the vehicle
control. When PHA680632 was combined with IR (one fraction of
8Gy irradiation) using the same dose of PHA680632, an additive
effect on the TGD has been found in p53 /  HCT116 compared
with IR alone. P-values for PHA680632 vs IRþPHA680632 and
IR vs IRþPHA680632 are 0.0003 and 0.0685, respectively. This
suggests that PHA680632 could increase tumour response in
combination with irradiation (Figure 6).
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sDISCUSSION
Enhanced radiation-induced cell killing effect in vitro by
siRNA Aurora-A silencing and a selective Aurora kinase
inhibitor, PHA680632
In this study, we analysed the potential effects of Aurora-A kinase
inhibition on tumour response to IR using RNAi or a novel
selective inhibitor of Aurora kinases, PHA680632, which strongly
inhibits the phosphorylation of T288 Aurora-A. It has previously
been shown that cells fail to divide after the exposure of
PHA680632, yielding polyploid cells leading to a reduction in
viability in vitro and tumour xenograft regression in mice (Soncini
et al, 2006). Inhibition of Aurora-A by siRNA Aurora-A or by
PHA680632 led to an enhancement of cell killing after exposure to
IR in several cell lines in vitro. Moreover, we demonstrated that
PHA680632 alone could induce a marked tumour growth
inhibition in vivo and that the combination of PHA680632 and
IR could lead to an increased tumour growth inhibition as
compared with PHA680632 or IR alone. In our study, low dose
PHA680632 did not induce polyploidy while a relatively high dose
induced significant polyploidy (data not shown). The PHA680632
concentrations used in our colony formation experiments
inhibited very little phospho-histone H3 on serine 10 (data not
shown). This might reflect the fact that at low concentrations,
PHA680632 potentially exerts more inhibitory effects on Aurora-A
than on Aurora-B (IC50 on Aurora-A and Aurora-B 27 and 135nM,
respectively). Thus, we chose a relatively low concentration of
PHA680632, expecting optimal Aurora-A selectivity.
P53 influence on response to Aurora-A inhibition by
siRNA or PHA680632 combined with irradiation
The combination of both Aurora-A inhibition and radiation led
to an increase in the percentage of annexin V-stained cells as well
as an increase in micronuclei formation in p53 /  cells when
compared to cells exposed to irradiation alone, suggesting that
these cells might undergo not only apoptosis but also mitotic
catastrophe. An increase in Brca1 foci formation 4h after
irradiation was also observed in p53 /  cells exposed to
PHA680632 when compared to cells exposed to irradiation only.
Of interest, in the context of a functional p53, exposure to
PHA680632 or transfection by siRNA Aurora-A did not increase
either the number of apoptotic cells or the number of micronuclei
or the Brca1 foci after IR when compared to cells exposed to IR
only. This strongly suggests a pivotal role for p53 in response to IR
after inhibition of Aurora-A kinase.
Clonogenic survival curves did show the same influence of p53
in response to IR after exposure to PHA680632 or siRNA Aurora-A
transfection. However, the impact of this treatment on apoptosis,
micronuclei, and Brca1 foci formation after IR did not translate
into synergistic enhancement of radiation-induced cell killing.
Indeed, we were only able to detect an additive effect of Aurora-A
inhibition after Aurora-A inhibition and exposure to IR in p53
non-functional cells using the colony formation survival assays.
G2–M arrest prevents cells from initiating mitosis when they
experience DNA damage during G2, or when they progress into G2
with some unrepaired damage (Kastan and Bartek, 2004). p53-
independent mechanisms are sufficient to sustain G2 arrest
(Kastan and Bartek, 2004) after DNA damage by irradiation.
Therefore, interfering with the G2–M checkpoint could be a
potential strategy to sensitise cancer cells to ionising radiation
(IR). Some authors have suggested that when both checkpoints
(such as G1–S and G2–M checkpoint) did not function, cells were
more easily sensitised to DNA damaging agents (Zhou and Bartek,
2004). This could be a possible reason for the enhanced radiation
response after Aurora-A inhibition in p53-deficient cells.
The integrity of the p53-p21Cip/WAF1-dependent postmitotic
checkpoint governs the response to Aurora-A inhibition. It was
recently shown that endoreduplication and apoptosis in response
to VX-680 are markedly enhanced in cells lacking p53. The
difference in response to VX-680 among these cell lines correlates
with the timing of induction of p21Cip/WAF1 and its ability to
inhibit cyclin E-cdk2 activity (Gizatullin et al, 2006). These data
also suggest the interplay between p53, its downstream effectors,
and Aurora-A.
PHA680632 brought about additive interaction with radiation in
terms of induced cell death in p53 non-functional cells. Such
additivity may be beneficial in chemo-radiotherapeutic combina-
tions. Indeed, supra-additive interaction may lead to acute
hypertoxicity, reduction of the maximum tolerated doses of both
drug and radiation and treatment failure. Contrary to a widely held
opinion, radiosensitisation should be considered with care when it
comes to eliciting inhibition of radiation recovery (Balosso et al,
1995). Well-known examples of limiting toxicities are adriamycin
(Mayer et al, 1976) and bleomycin (Peters et al, 1988).
It should be recalled here that among the most useful
mechanisms in chemo-radiotherapeutic combinations are spatial
cooperation, reoxygenation, and inhibition of tumour repopula-
tion. Reduction in tumour volume after chemotherapy, when it
occurs, may result in improved blood supply to the tumour,
leading to reoxygenation and increased radiosensitivity (Hennequin
and Favaudon, 2002). PHA680632 and radiotherapy might be used
concomitantly or in close temporal proximity, potentially without
acute or late healthy tissue complications.
In conclusion, we demonstrate that Aurora-A inhibition by the
Aurora kinase inhibitor, PHA680632, in association with radiation
leads to an additive effect in cancer cells, especially in p53-deficient
cells but does not act as a radiosensitiser in vitro or in vivo.
However, further experiments are needed for a better under-
standing of the interplay between the molecular checkpoints that
are activated by IR and the consequences of Aurora kinases
inhibition. The results suggest the importance of Aurora-A kinase
targeting in combination with IR.
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